• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Combivent (ipratropium bromide and albuterol sulfate) Aerosol

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2011 and August 2012


August 2012

Summary View



Post-Marketing Experience
  • Metabolic acidosis has been reported with use of albuterol-containing products.


April 2011

Summary View



Immediate Hypersensitivity Reaction
  • ...“If such reaction occurs, therapy with Combivent Inhalation Aerosol should be stopped at once and alternative treatment should be considered.”



Information for Patients
  • ...“Since dizziness, accommodation disorder, mydriasis, and blurred vision may occur with use of Combivent, patients ...
Drug Interactions
  • “Consider monitoring potassium levels”
  • “Consider alternative therapy in patients taking MAOs or tricyclic antidepressants.”
Nursing Mothers
  • deleted “it is unlikely that the active component...



  • “pruritus” added
Postmarketing Experiences
  • “hypersensitivity, pharyngeal edema, ... diastolic blood pressure decreased, and systolic blood pressure increased.”